Macrogenics, Inc. revenue by segment MGNX

Annual Quarterly

Macrogenics, Inc. splits its revenue into 5 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Revenue From Collaborative Agreements at $25.5 million, 78% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Jun 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Revenue	175	33	21	41	73	7	13	19	111
Revenue From Collaborative Agreements	—	25 +358.6% share 77.6%	1 share 2.7%	20 +48.2% share 49.2%	53 -47.7% share 72.8%	6 share 80.9%	—	14 share 70.7%	101 share 91.6%
Contract Manufacturing	—	—	14 +128.5% share 67.6%	11 +240.1% share 27.3%	20 +333.8% share 27.2%	15 share 223.8%	6 share 46.6%	3 share 17.1%	5 share 4.1%
Revenue From Royality Agreements Member	—	7 +460.2% share 22.4%	6 +1291.6% share 29.6%	—	—	1 share 19.1%	0 share 3.4%	—	—
Product	—	—	—	—	—	—	—	2 share 11.1%	4 share 3.8%
Revenue From Government Agreements	—	—	—	—	—	—	—	0 share 1.1%	1 share 0.5%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: MGNX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Rockville, MD
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1125345

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.